View ValuationRootK 将来の成長Future 基準チェック /06現在、 RootKの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Machinery 収益成長27.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.お知らせ • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).分析記事 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).分析記事 • Nov 05Abpro Bio Co., Ltd.'s (KOSDAQ:195990) 27% Price Boost Is Out Of Tune With RevenuesAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders are no doubt pleased to see that the share price has bounced 27% in...New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩69.2b market cap, or US$47.9m).分析記事 • Nov 03Would Abpro Bio (KOSDAQ:195990) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Aug 18Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 27%KOSDAQ:A195990 1 Year Share Price vs Fair Value Explore Abpro Bio's Fair Values from the Community and select yours The...分析記事 • Jul 25Abpro Bio (KOSDAQ:195990) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risk Market cap is less than US$100m (₩85.7b market cap, or US$62.4m).New Risk • Mar 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩22b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩22b). Market cap is less than US$100m (₩88.0b market cap, or US$60.0m).お知らせ • Mar 19Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 70, techno sunhwan-ro 1-gil, yuga-eup, dalseong-gun, daegu South Korea分析記事 • Mar 12Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Share Price Could Signal Some RiskAbpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...New Risk • Dec 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.分析記事 • Dec 06Abpro Bio Co., Ltd. (KOSDAQ:195990) Shares May Have Slumped 29% But Getting In Cheap Is Still UnlikelyAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders won't be pleased to see that the share price has had a very rough...New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Market cap is less than US$100m (₩138.1b market cap, or US$98.6m).分析記事 • Oct 21We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Aug 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩9.7b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩126.7b market cap, or US$94.9m).分析記事 • Jul 12Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is UnlikelyWhen close to half the companies in the Machinery industry in Korea have price-to-sales ratios (or "P/S") below 1x, you...New Risk • Jun 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩136.1b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩136.1b market cap, or US$97.8m).お知らせ • Jun 18Abpro Bio Co., Ltd. announced that it has received KRW 6 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On June 17, 2024, Abpro Bio Co., Ltd. closed the transaction.New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (₩137.8b market cap, or US$99.6m).分析記事 • Mar 14Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)Abpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 6.4x may look like a poor investment...New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.6b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (₩130.6b market cap, or US$98.9m).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 28Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion.Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion on September 26, 2022. As per the terms, the offer per share is KRW 3348 per share. Total number of shares acquired are 11,049,646. Transaction is expected to be closed on November 8, 2022.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.お知らせ • Jun 17Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment ArmAbpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.分析記事 • Apr 05Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 17New 90-day low: ₩1,055The company is down 58% from its price of ₩2,515 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.分析記事 • Feb 02Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last YearAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders might be concerned after seeing the share price drop 27% in the last...Is New 90 Day High Low • Nov 17New 90-day high: ₩1,490The company is up 110% from its price of ₩710 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 13% over the same period.Is New 90 Day High Low • Nov 02New 90-day high: ₩834The company is up 5.0% from its price of ₩797 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is down 3.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、RootK は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A195990 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202630,937-43,585-11,726-9,765N/A12/31/202531,923-48,920-8,813-6,686N/A9/30/202536,183-70,029-22,113-9,689N/A6/30/202541,588-61,340-20,206-7,620N/A3/31/202534,429-18,168-19,124-8,077N/A12/31/202431,663-15,629-21,668-5,752N/A9/30/202427,416-6,892-6,703-601N/A6/30/202418,585-20,162-9,715-4,663N/A3/31/202423,327-22,452-8,917-2,777N/A12/31/202325,375-25,742-7,101-4,862N/A9/30/202325,836-16,074-8,400-8,512N/A6/30/202325,873-11,933-10,013-10,192N/A3/31/202324,851-10,475-12,529-12,921N/A12/31/202222,112-8,145-11,247-12,461N/A9/30/202220,595-11,937-13,790-11,854N/A6/30/202224,674-6,590-11,150-8,384N/A3/31/202226,136-11,169-8,440-5,032N/A12/31/202132,914-9,255-6,007-2,220N/A9/30/202142,613-33,63110,87813,521N/A6/30/202145,552-37,6166,6958,896N/A3/31/202143,897-39,6674,9536,251N/A12/31/202035,797-42,1102,1072,761N/A9/30/202024,386-29,574-8,664-7,307N/A6/30/202015,585-40,742-4,043-2,557N/A3/31/202020,995-33,925242,321N/A12/31/201931,930-32,724N/A2,673N/A9/30/201936,110-20,842N/A998N/A6/30/201953,787-9,337N/A3,365N/A3/31/201960,322-10,811N/A-1,491N/A12/31/201858,857-9,390N/A2,466N/A9/30/201866,323-7,136N/A-17,881N/A6/30/201854,066-11,118N/A-23,985N/A3/31/201850,929-7,449N/A-18,581N/A12/31/201745,944-11,626N/A-34,216N/A9/30/201738,589-8,267N/A-17,929N/A6/30/201742,120-6,125N/A-26,246N/A3/31/201743,467-4,615N/A-29,177N/A12/31/201649,52117N/A-10,497N/A9/30/201653,1282,581N/A-8,675N/A6/30/201650,7683,794N/A7,844N/A3/31/201664,1305,601N/A-5,154N/A12/31/201577,10115,021N/A-325N/A9/30/201595,49619,567N/A-950N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A195990の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A195990の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A195990の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A195990の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A195990の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A195990の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/30 09:30終値2026/06/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋RootK Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.
お知らせ • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.
Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
分析記事 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...
New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).
分析記事 • Nov 05Abpro Bio Co., Ltd.'s (KOSDAQ:195990) 27% Price Boost Is Out Of Tune With RevenuesAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders are no doubt pleased to see that the share price has bounced 27% in...
New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩69.2b market cap, or US$47.9m).
分析記事 • Nov 03Would Abpro Bio (KOSDAQ:195990) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Aug 18Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 27%KOSDAQ:A195990 1 Year Share Price vs Fair Value Explore Abpro Bio's Fair Values from the Community and select yours The...
分析記事 • Jul 25Abpro Bio (KOSDAQ:195990) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risk Market cap is less than US$100m (₩85.7b market cap, or US$62.4m).
New Risk • Mar 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩22b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩22b). Market cap is less than US$100m (₩88.0b market cap, or US$60.0m).
お知らせ • Mar 19Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 70, techno sunhwan-ro 1-gil, yuga-eup, dalseong-gun, daegu South Korea
分析記事 • Mar 12Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Share Price Could Signal Some RiskAbpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...
New Risk • Dec 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
分析記事 • Dec 06Abpro Bio Co., Ltd. (KOSDAQ:195990) Shares May Have Slumped 29% But Getting In Cheap Is Still UnlikelyAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders won't be pleased to see that the share price has had a very rough...
New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Market cap is less than US$100m (₩138.1b market cap, or US$98.6m).
分析記事 • Oct 21We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Aug 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩9.7b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩126.7b market cap, or US$94.9m).
分析記事 • Jul 12Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is UnlikelyWhen close to half the companies in the Machinery industry in Korea have price-to-sales ratios (or "P/S") below 1x, you...
New Risk • Jun 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩136.1b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩136.1b market cap, or US$97.8m).
お知らせ • Jun 18Abpro Bio Co., Ltd. announced that it has received KRW 6 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On June 17, 2024, Abpro Bio Co., Ltd. closed the transaction.
New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (₩137.8b market cap, or US$99.6m).
分析記事 • Mar 14Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)Abpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 6.4x may look like a poor investment...
New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.6b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (₩130.6b market cap, or US$98.9m).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 28Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion.Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion on September 26, 2022. As per the terms, the offer per share is KRW 3348 per share. Total number of shares acquired are 11,049,646. Transaction is expected to be closed on November 8, 2022.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
お知らせ • Jun 17Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment ArmAbpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.
分析記事 • Apr 05Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 17New 90-day low: ₩1,055The company is down 58% from its price of ₩2,515 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.
分析記事 • Feb 02Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last YearAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders might be concerned after seeing the share price drop 27% in the last...
Is New 90 Day High Low • Nov 17New 90-day high: ₩1,490The company is up 110% from its price of ₩710 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 13% over the same period.
Is New 90 Day High Low • Nov 02New 90-day high: ₩834The company is up 5.0% from its price of ₩797 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is down 3.0% over the same period.